U.S. Markets closed

Sabra Health Care price target raised to $29 from $24 at RBC Capital

RBC Capital increased its target on Sabra after the company reported higher than expected Q4 normalized AFFO and revenue. The firm thinks the company's investment activity is solid and it maintains a Buy rating.